Press Releases

The biopharmaceutical company is testing with multiple U.S. military branches at Northern Strike to provide Bexson’s BB106 ketamine therapy for pain management for contested environments.

Bexson Biomedical’s CEO, Gregg Peterson, demonstrated the AKESO wearable drug delivery device and discussed the Company’s BB106 ketamine therapy for pain management. 

Bexson Biomedical today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.

Bexson Biomedical announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association’s (PDA) 2022 Drug Delivery Innovation Partnership Award.

Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are scheduled to present on Thursday, September 22nd, 2022 in New York City, NY and will discuss various new and innovative therapies for the treatment of mental health. Management will be participating in investor one-on-one meetings while in attendance.

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced the appointment of Robert S. Langer ScD, MIT David H. Koch Institute Professor and Co-founder of Moderna, to its Scientific Advisory Board (SAB).

Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their collaboration...

Bexson's lead formulation involves ketamine, which blocks the NMDA receptor, a fundamental unit in pain signaling. Ketamine is already delivered by doctors in management of severe pain through intravenous infusion, but healthcare providers are limited by current formulations, thus reducing access and increasing the procedural cost of care.

BB106 is formulated for subcutaneous delivery, which could make ketamine-based pain management a viable alternative to opioids.

Sheldon Moberg joins Bexson as Senior VP Drug Delivery, where he'll lead the development of proprietary devices that can make controlled substances and other therapies more accessible.

Capital will be used to further develop the Company's proprietary ketamine therapies and a wearable device for delivery of controlled substances.

Bexson Biomedical, Inc. will be co-hosting "The Ketamine Conference – A Molecular Masterclass" on August 21-22. The two-day virtual conference will include 12 different panel sessions focused on the latest science, clinical innovations, and investment opportunities with ketamine. Experts from around the globe will be participating as panel speakers and moderators.

Bexson Biomedical, Inc. today announced the expansion of its Board of Directors with the addition of Itai Danovitch, MD, MBA. Dr. Danovitch is an independent director and brings extensive experience guiding innovative biopharma companies from start-up through accelerated growth.

Bexson Biomedical's Chief Scientific Officer, Jeffrey Becker, M.D., recently spoke at the annual meeting for the American Society of Ketamine Physicians (ASKP) in Denver, CO. Clinicians and multi-disciplinary thought leaders from around the country and world attended ASKP's two-day conference focused on the latest research and clinical best practices for ketamine, a drug that is finding increasing utility for a wide range of disorders in pain management and mental health.